Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794958 | 1.00 | SIGMAR1 (0.59) | SIGMAR1BCHETLR2CNR2GAA | |
| SCHEMBL2794487 | 1.00 | SIGMAR1 (0.59) | SIGMAR1BCHETLR2CNR2GAA | |
| SCHEMBL667265 | 0.98 | SIGMAR1 (0.58) | SIGMAR1BCHETLR2CNR2GAA | |
| SCHEMBL666714 | 0.98 | SIGMAR1 (0.58) | SIGMAR1BCHETLR2CNR2GAA | |
| SCHEMBL19868618 | 0.98 | SIGMAR1 (0.58) | SIGMAR1BCHETLR2CNR2GAA | |
| SCHEMBL27919164 | 0.98 | SIGMAR1 (0.58) | SIGMAR1BCHETLR2CNR2GAA | |
| Hydrochloric Acid SCHEMBL1330333 | 0.97 | SIGMAR1 (0.56) | SIGMAR1BCHETLR2CNR2GAA | |
| Bromide SCHEMBL1330640 | 0.97 | SIGMAR1 (0.56) | SIGMAR1BCHETLR2CNR2GAA | |
| Bromide SCHEMBL1330662 | 0.97 | SIGMAR1 (0.56) | SIGMAR1BCHETLR2CNR2GAA | |
| Hydrochloric Acid SCHEMBL1329672 | 0.97 | SIGMAR1 (0.56) | SIGMAR1BCHETLR2CNR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389415-B2 | Methods of regulating cannabinoid receptor activity-related disorders and diseases | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-07-19 | — | — | US | disclosed |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20210038540-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2021-02-11 | — | — | US | disclosed |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-25 | — | — | US | disclosed |
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-04-14 | — | — | US | disclosed |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | The USA, as represented by the Secretary, Departme nt of Health and Human Services (US) | 2019-01-10 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
| WO-2011112867-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112867-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-07-01 | — | — | US | disclosed |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-07-01 | — | — | US | disclosed |
| CN-101528666-A | Preparation of (R, R) -fenoterol and (R, R) -or (R, S) -fenoterol analogues and their use in the treatment of congestive heart failure | US GOVERNMENT (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2064174-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008022038-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008022038-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TLR2 405/4885 |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TLR2 436/4885 |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TLR2 436/4885 |
| US-11389415-B2 | Methods of regulating cannabinoid receptor activity-related disorders and diseases | CNR1, CNR2, GPR68 | SIGMAR1 1039/4885BCHE 925/4885TLR2 1690/4885 |
| US-20210038540-A1 | METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES | CNR1, CNR2, GPR68 | SIGMAR1 1039/4885BCHE 925/4885TLR2 1690/4885 |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | SIGMAR1 332/4885BCHE 3059/4885TLR2 457/4885 |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TLR2 436/4885 |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TLR2 405/4885 |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TLR2 436/4885 |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TLR2 405/4885 |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TLR2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.